1. Yang, F#., Samuel, W. B#., Tang ,C#., Sun, HY#., Du, LJ#., Malwine, B., Ma, XT., Chen ,Y., Fang, HS., Li, XM., Pkolekar., Omkar P., Cai, JY., Ding, LX., Wang, TY., Arend, S., Shen, SH., Cornelia, E., Jeffery, M., Chen, HZ., Duan, CW., Liu, Y., Li, H., Li, B., Renate, KS*., Zhang, J*., Zhou, B.-B *. “Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse”, Nature Cancer, 2021, in press.
2. Li, B., Brady, SW., Ma, X., Shen, S., Zhang, Y., Li, Y., Szlachta, K., Dong, L., Liu, Y., Yang, F., Wang, N., Flasch, DA., Myers, MA., Mulder, HL., Ding, L., Liu, Y., Tian, L., Hagiwara, K., Xu, K., Zhou, X., Sioson, E., Wang, T., Yang, L., Zhao, J., Zhang, H., Shao, Y., Sun, H., Sun, L., Cai, J., Sun, HY., Lin, TN., Du, L., Li, H., Rusch, M., Edmonson, MN., Easton, J., Zhu, X., Zhang, J., Cheng, C., Raphael, BJ., Tang, J., Downing, JR., Alexandrov, LB., Zhou, B.-B *., Pui, CH*., Yang, JJ*., Zhang, J*. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135(1):41-55
3. Chen,YL., Tang, C., Zhang, MY., Huang, WL., Xu, Y., Sun, HY., Yang, F., Song, LL., Wang, H., Mu,LL., Li, MH., Zheng, WW., Miao, Y., Ding, LX., Li, BS., Shen,SH., Liu, SL., Li, H., Zhu, ZQ., Chen,HW., Tang,ZH., Chen,J., Hong, DL., Chen,HZ., Duan CW., Zhou, B.-B. Blocking ATM-dependent NF-κB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia. Leukemia. 2019, 33(10):2365-2378.
4. Du, LJ., Yang, F., Fang, HS., Sun, HY., Chen, Y., Xu, Y., Li, H., Zheng, L., Zhou, B.-B. AICAr suppresses cell proliferation by inducing NTP and dNTP pool imbalances in acute lymphoblastic leukemia cells, 2019, 33(3): FASEB J., 2019, 33(3):4525-4537.
5. Li, B., Li, H., Bai, Y., Kirschner-Schwabe, R., Yang, J., Chen, Y., Lu, G., Tzoneva, G., Ma, X., Wu, T., Li, W., Lu, H., Ding, L., Liang, H., Huang, X., Yang, M., Jin, L., Kang, H., Chen, S., Du, A., Shen, S., Ding, J., Chen, H., Chen, J., von Stackelberg, A., Gu, L., Zhang, J., Ferrando, A., Tang, J., Wang, S., Zhou, B,-B. (2015) “Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.” Nat Med,21(6):563-571 (cover story).
6. Damelin, M, Geles, K., Follettie, M., Yuan, P., Baxter, M., Golas, J., DiJoseph, J., Karnoub, M., Huang, S., Diesl, V., Behrens, C., Sung, C., Rios, C., Gruzas, J., Sridharan, L., Dougher, M., Kunz, A., Hamann, P., Evans, D., Armellino, D., Khandke, K., Marquette, K., Tchistiakova, L., Boghaert, E., Abraham, R., Wistuba, I., and Zhou, B.-B. (2011) “Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells”. Cancer Research, 71(12): 4236-4246
7. Zhou, B.-B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., Yang, G., Yao, W., Vaddi, K., Gazdar, A., Friedman, S., Jablons, D., S., Newton, R., Fridman, J., Minna, J, Scherle, P. (2006) “Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.” Cancer Cell, 10(1): 39-50.(cover story)
8. Zhou, B.-B. and Bartek, J. (2004) “Targeting the checkpoint kinases: chemosensitization versus chemoprotection.” Nature Rev. Cancer,4(3), 216-225
9. Zhou, B.-B. and Elledge, S. J. (2000) "The DNA damage response: putting checkpoints in perspective." Nature, 408, 433-439
导师风采
返回
